Platelet monoamine oxidase B: use and misuse.

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Human platelets possess mitochondrial monoamine oxidase (MAO) type B, an enzyme also prevalent in the human brain.
• This enzyme actively metabolizes substrates such as tyramine, dopamine, phenylethylamine, the anticonvulsant milacemide, and MPTP.

Purpose of the Study:

• To investigate the role and potential applications of platelet MAO-B in pharmacological research.
• To explore the utility of platelet MAO-B as a biomarker for monitoring anti-Parkinsonian drug activity.
• To assess the potential of MAO-B substrates as prodrugs for delivering neuroactive substances.

Main Methods:

• Characterization of MAO-B activity in human platelets.
• Assessment of MAO-B substrate oxidation, including milacemide and MPTP.
• Evaluation of selective MAO-B inhibition by 1-deprenyl.

Main Results:

• Platelet MAO-B selectively oxidizes specific substrates, with minimal impact on serotonin (5-HT) oxidation.
• 1-Deprenyl selectively inhibits platelet MAO-B, suggesting its potential for monitoring anti-Parkinsonian drug efficacy.
• Milacemide is oxidized by MAO-B to glycine, indicating potential for prodrug development.

Conclusions:

• Platelet MAO-B serves as a viable model for studying brain MAO-B activity and its inhibition.
• Platelet MAO-B activity can be monitored using plasma metabolite levels, offering insights into brain MAO-B function.
• The findings support the development of MAO-B-metabolized prodrugs for therapeutic applications.